...
【24h】

Body mass index and breast cancer treatment-related lymphedema.

机译:体重指数与乳腺癌治疗相关的淋巴水肿。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The main purpose was to examine longitudinally the influence of body mass index (BMI) and obesity on the development of breast cancer treatment-related lymphedema. We asked, does elevated BMI increase lymphedema risk? METHODS: A secondary analysis was conducted on de-identified data collected from 138 newly diagnosed breast cancer survivors who had arm-volume measurements and symptom assessment at pre-treatment baseline and measurements up to 30 months post-surgery in a prospective longitudinal parent study. Arm volume and weight data, part of the information collected during each participant visit, were examined. RESULTS: Breast cancer survivors whose BMI was >/=30 at the time of breast cancer treatment were approximately 3.6 times more likely to develop lymphedema at 6 months or greater after diagnosis than those with a BMI < 30 at the time of cancer treatment (95% confidence interval, C.I., for odds ratio, O.R., 1.42-9.04; p = 0.007). Those with a general BMI increase or a BMI rise to 30 or greater during their first 30 months of survivorship were not more likely to develop late-onset lymphedema than those who did not have similar changes in BMI. CONCLUSIONS: Pre-treatment BMI may be a risk factor for lymphedema. Weight gain post-treatment may not be. Further research is warranted.
机译:目的:主要目的是纵向检查体重指数(BMI)和肥胖对与乳腺癌相关的淋巴水肿发展的影响。我们问过,BMI升高会增加淋巴水肿风险吗?方法:对前瞻性纵向父母研究中从138名新诊断的乳腺癌幸存者中收集的身份不明数据进行了二次分析,这些幸存者在治疗前的基线进行了臂体积测量和症状评估,并在术后30个月进行了测量。检查了手臂的体积和重量数据,这是每次参与者访问期间收集的部分信息。结果:在乳腺癌治疗后BMI> / = 30的乳腺癌幸存者在诊断后6个月或更长时间出现淋巴水肿的可能性是在癌症治疗时BMI <30的人的3.6倍(95)可信度百分比置信区间CI(OR为1.42-9.04; p = 0.007)。与未发生类似BMI变化的患者相比,在最初的生存期30个月中BMI总体升高或BMI升高至30或更高的患者发生迟发性淋巴水肿的可能性较小。结论:治疗前体重指数可能是淋巴水肿的危险因素。治疗后体重增加可能不会。值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号